KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShort-Term Debt repayments
Ratios

Pfizer (PFE) Short-Term Debt repayments (2016 - 2025)

Pfizer (PFE) has disclosed Short-Term Debt repayments for 13 consecutive years, with $151.0 million as the latest value for Q2 2025.

  • Quarterly Short-Term Debt repayments fell 96.66% to $151.0 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $2.2 billion for FY2025, 80.41% down from the prior year.
  • Short-Term Debt repayments for Q2 2025 was $151.0 million at Pfizer, down from $2.0 billion in the prior quarter.
  • The five-year high for Short-Term Debt repayments was $7.8 billion in Q3 2024, with the low at $1.0 million in Q4 2021.
  • Average Short-Term Debt repayments over 5 years is $2.3 billion, with a median of $1.2 billion recorded in 2024.
  • The sharpest move saw Short-Term Debt repayments tumbled 99.99% in 2021, then soared 388600.0% in 2022.
  • Over 5 years, Short-Term Debt repayments stood at $1.0 million in 2021, then skyrocketed by 388600.0% to $3.9 billion in 2022, then crashed by 99.92% to $3.0 million in 2023, then skyrocketed by 259033.33% to $7.8 billion in 2024, then crashed by 98.06% to $151.0 million in 2025.
  • According to Business Quant data, Short-Term Debt repayments over the past three periods came in at $151.0 million, $2.0 billion, and $7.8 billion for Q2 2025, Q1 2025, and Q3 2024 respectively.